Is red wine a healthier choice than white wine? Uncorking the cancer risks
A common perception is that not all alcoholic beverages are alike. Red wine, for instance,…
Author ONA Editor
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
S3E2 The Oncology Journal Club: Is DEI Dead? The Future of Diversity, Equity and Inclusion in Healthcare
Welcome to Episode 2 of the third series of The Oncology Journal Club. Our Host Craig Underhill is joined by Dr Kate Clarke and Professor Christopher Jackson to digest how political changes in the US will have a wider impact on oncology care and research globally.
New avenues in breast cancer treatment: The role of ubiquitin-specific proteases in programmed cell death
This review highlights the critical role of ubiquitin-specific proteases (USPs) in regulating programmed cell death…
Research by scientists upends scientific understanding of how anticancer drugs kill cancer
Research by UMass Chan Medical School scientists Sharon Cantor, PhD, and Jenna M. Whalen, PhD, poses…
Innovative dual-target drug may lead to new investigational approach for breast cancer patients
Researchers, led by the University of Melbourne’s Professor Laura Mackay, a Laboratory Head, and Immunology Theme…
Scientists discover the ‘roadmap’ that aggressive cancer uses to spread around the body
Scientists have discovered a new way to predict which tumours will become aggressive before they…
ASCO GU 2025: Some kidney cancer patients can stop combination treatment after two years
A new study presented today by researchers at Fox Chase Cancer Center shows that some…
New approach identifies reproducible VOCs for lung cancer diagnosis
A research team led by Prof. CHU Yannan from the Hefei Institutes of Physical Science…
Immunotherapy against melanoma: efficacy can be predicted with a chip
A team of researchers from the European Institute of Oncology and the Politecnico di Milano,…
FDA approves vimseltinib for symptomatic tenosynovial giant cell tumour
On February 14, 2025, the Food and Drug Administration approved vimseltinib, a kinase inhibitor, for…